Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 343

1.

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.

He J, McLaughlin RP, van der Noord V, Foekens JA, Martens JWM, van Westen G, Zhang Y, van de Water B.

Breast Cancer Res Treat. 2019 Aug 6. doi: 10.1007/s10549-019-05380-z. [Epub ahead of print]

PMID:
31388935
2.

Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes.

Koedoot E, Fokkelman M, Rogkoti VM, Smid M, van de Sandt I, de Bont H, Pont C, Klip JE, Wink S, Timmermans MA, Wiemer EAC, Stoilov P, Foekens JA, Le Dévédec SE, Martens JWM, van de Water B.

Nat Commun. 2019 Jul 5;10(1):2983. doi: 10.1038/s41467-019-11020-3.

3.

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.

McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, Smid M, Zhang Y, van de Water B.

Breast Cancer Res. 2019 Jul 1;21(1):77. doi: 10.1186/s13058-019-1161-9.

4.

MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines.

Uhr K, Prager-van der Smissen WJC, Heine AAJ, Ozturk B, van Jaarsveld MTM, Boersma AWM, Jager A, Wiemer EAC, Smid M, Foekens JA, Martens JWM.

PLoS One. 2019 May 7;14(5):e0216400. doi: 10.1371/journal.pone.0216400. eCollection 2019.

5.

Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation.

Brinkman AB, Nik-Zainal S, Simmer F, Rodríguez-González FG, Smid M, Alexandrov LB, Butler A, Martin S, Davies H, Glodzik D, Zou X, Ramakrishna M, Staaf J, Ringnér M, Sieuwerts A, Ferrari A, Morganella S, Fleischer T, Kristensen V, Gut M, van de Vijver MJ, Børresen-Dale AL, Richardson AL, Thomas G, Gut IG, Martens JWM, Foekens JA, Stratton MR, Stunnenberg HG.

Nat Commun. 2019 Apr 15;10(1):1749. doi: 10.1038/s41467-019-09828-0.

6.

Co-regulated gene expression of splicing factors as drivers of cancer progression.

Koedoot E, Smid M, Foekens JA, Martens JWM, Le Dévédec SE, van de Water B.

Sci Rep. 2019 Apr 2;9(1):5484. doi: 10.1038/s41598-019-40759-4.

7.

The circular RNome of primary breast cancer.

Smid M, Wilting SM, Uhr K, Rodríguez-González FG, de Weerd V, Prager-Van der Smissen WJC, van der Vlugt-Daane M, van Galen A, Nik-Zainal S, Butler A, Martin S, Davies HR, Staaf J, van de Vijver MJ, Richardson AL, MacGrogan G, Salgado R, van den Eynden GGGM, Purdie CA, Thompson AM, Caldas C, Span PN, Sweep FCGJ, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Paradiso A, Eyfjord J, Broeks A, Vincent-Salomon A, Futreal AP, Knappskog S, King T, Viari A, Børresen-Dale AL, Stunnenberg HG, Stratton M, Foekens JA, Sieuwerts AM, Martens JWM.

Genome Res. 2019 Mar;29(3):356-366. doi: 10.1101/gr.238121.118. Epub 2019 Jan 28.

PMID:
30692147
8.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
9.

Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers.

Weerts MJA, Smid M, Foekens JA, Sleijfer S, Martens JWM.

Cancers (Basel). 2018 Dec 9;10(12). pii: E500. doi: 10.3390/cancers10120500.

10.

An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA.

Vitale SR, Sieuwerts AM, Beije N, Kraan J, Angus L, Mostert B, Reijm EA, Van NM, van Marion R, Dirix LY, Hamberg P, de Jongh FE, Jager A, Foekens JA, Vigneri P, Sleijfer S, Jansen MPHM, Martens JWM.

J Mol Diagn. 2019 Jan;21(1):123-137. doi: 10.1016/j.jmoldx.2018.08.010. Epub 2018 Oct 6.

PMID:
30296589
11.

Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer.

Uhr K, Sieuwerts AM, de Weerd V, Smid M, Hammerl D, Foekens JA, Martens JWM.

Sci Rep. 2018 Jun 25;8(1):9657. doi: 10.1038/s41598-018-27987-w.

12.

Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons.

Smid M, Coebergh van den Braak RRJ, van de Werken HJG, van Riet J, van Galen A, de Weerd V, van der Vlugt-Daane M, Bril SI, Lalmahomed ZS, Kloosterman WP, Wilting SM, Foekens JA, IJzermans JNM; MATCH study group, Martens JWM, Sieuwerts AM.

BMC Bioinformatics. 2018 Jun 22;19(1):236. doi: 10.1186/s12859-018-2246-7.

13.

Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA.

Weerts MJA, Timmermans EC, van de Stolpe A, Vossen RHAM, Anvar SY, Foekens JA, Sleijfer S, Martens JWM.

Neoplasia. 2018 Jul;20(7):687-696. doi: 10.1016/j.neo.2018.05.003. Epub 2018 May 26.

14.

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.

de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S.

Cancers (Basel). 2018 May 5;10(5). pii: E134. doi: 10.3390/cancers10050134.

15.

Confirmation of a metastasis-specific microRNA signature in primary colon cancer.

Coebergh van den Braak RRJ, Sieuwerts AM, Lalmahomed ZS, Smid M, Wilting SM, Bril SI, Xiang S, van der Vlugt-Daane M, de Weerd V, van Galen A, Biermann K, van Krieken JHJM, Kloosterman WP, Foekens JA; MATCH study group*, Martens JWM, IJzermans JNM.

Sci Rep. 2018 Mar 27;8(1):5242. doi: 10.1038/s41598-018-22532-1.

16.

T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression.

Mustafa DAM, Pedrosa RMSM, Smid M, van der Weiden M, de Weerd V, Nigg AL, Berrevoets C, Zeneyedpour L, Priego N, Valiente M, Luider TM, Debets R, Martens JWM, Foekens JA, Sieuwerts AM, Kros JM.

Acta Neuropathol. 2018 Apr;135(4):581-599. doi: 10.1007/s00401-018-1806-2. Epub 2018 Jan 19.

17.

The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.

Aubele M, Schmitt M, Napieralski R, Paepke S, Ettl J, Absmaier M, Magdolen V, Martens J, Foekens JA, Wilhelm OG, Kiechle M.

Dis Markers. 2017;2017:4934608. doi: 10.1155/2017/4934608. Epub 2017 Sep 12. Review.

18.

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.

Beije N, Sieuwerts AM, Kraan J, Van NM, Onstenk W, Vitale SR, van der Vlugt-Daane M, Dirix LY, Brouwer A, Hamberg P, de Jongh FE, Jager A, Seynaeve CM, Jansen MPHM, Foekens JA, Martens JWM, Sleijfer S.

Mol Oncol. 2018 Jan;12(1):48-57. doi: 10.1002/1878-0261.12147. Epub 2017 Nov 17.

19.

High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients.

Coebergh van den Braak RRJ, Sieuwerts AM, Kandimalla R, Lalmahomed ZS, Bril SI, van Galen A, Smid M, Biermann K, van Krieken JHJM, Kloosterman WP, Foekens JA, Goel A, Martens JWM, IJzermans JNM; MATCH study group.

PLoS One. 2017 Sep 28;12(9):e0185607. doi: 10.1371/journal.pone.0185607. eCollection 2017.

20.

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer.

De Marchi T, Timmermans MA, Sieuwerts AM, Smid M, Look MP, Grebenchtchikov N, Sweep FCGJ, Smits JG, Magdolen V, van Deurzen CHM, Foekens JA, Umar A, Martens JW.

Sci Rep. 2017 May 18;7(1):2099. doi: 10.1038/s41598-017-02296-w.

21.

A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer.

Kloosterman WP, Coebergh van den Braak RRJ, Pieterse M, van Roosmalen MJ, Sieuwerts AM, Stangl C, Brunekreef R, Lalmahomed ZS, Ooft S, van Galen A, Smid M, Lefebvre A, Zwartkruis F, Martens JWM, Foekens JA, Biermann K, Koudijs MJ, Ijzermans JNM, Voest EE.

Cancer Res. 2017 Jul 15;77(14):3814-3822. doi: 10.1158/0008-5472.CAN-16-3563. Epub 2017 May 16.

22.

Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy.

Weerts MJA, Hollestelle A, Sieuwerts AM, Foekens JA, Sleijfer S, Martens JWM.

Clin Cancer Res. 2017 Aug 15;23(16):4735-4743. doi: 10.1158/1078-0432.CCR-17-0032. Epub 2017 Apr 18.

23.

Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation.

Dimitrakopoulos L, Prassas I, Berns EMJJ, Foekens JA, Diamandis EP, Charames GS.

Clin Chem Lab Med. 2017 Aug 28;55(9):1291-1304. doi: 10.1515/cclm-2016-0947.

PMID:
28157690
24.

Proteomic characterization of microdissected breast tissue environment provides a protein-level overview of malignant transformation.

Braakman RB, Stingl C, Tilanus-Linthorst MM, van Deurzen CH, Timmermans MA, Smid M, Foekens JA, Luider TM, Martens JW, Umar A.

Proteomics. 2017 Mar;17(5). doi: 10.1002/pmic.201600213.

25.

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.

Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, Brouwer A, de Jongh FE, Jager A, Seynaeve CM, Van NM, Foekens JA, Martens JW, Sleijfer S.

Neoplasia. 2016 Nov;18(11):647-653. doi: 10.1016/j.neo.2016.08.007. Epub 2016 Oct 17.

26.

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.

Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME, Sweep FC, Span PN, Foekens JA, Martens JW, Yee D, Harris RS.

Sci Adv. 2016 Oct 7;2(10):e1601737. eCollection 2016 Oct.

27.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

28.

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients.

Liu NQ, De Marchi T, Timmermans A, Trapman-Jansen AM, Foekens R, Look MP, Smid M, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Foekens JA, Martens JW, Umar A.

Sci Rep. 2016 Aug 25;6:32027. doi: 10.1038/srep32027.

29.

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.

Liu J, Sieuwerts AM, Look MP, van der Vlugt-Daane M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW.

PLoS One. 2016 Aug 23;11(8):e0161731. doi: 10.1371/journal.pone.0161731. eCollection 2016.

30.

Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk.

Liu J, Prager-van der Smissen WJ, Schmidt MK, Collée JM, Cornelissen S, Lamping R, Nieuwlaat A, Foekens JA, Hooning MJ, Verhoef S, van den Ouweland AM, Hogervorst FB, Martens JW, Hollestelle A.

Sci Rep. 2016 Jul 18;6:30026. doi: 10.1038/srep30026.

31.

Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer.

Onstenk W, Sieuwerts AM, Mostert B, Lalmahomed Z, Bolt-de Vries JB, van Galen A, Smid M, Kraan J, Van M, de Weerd V, Ramírez-Moreno R, Biermann K, Verhoef C, Grünhagen DJ, IJzermans JN, Gratama JW, Martens JW, Foekens JA, Sleijfer S.

Oncotarget. 2016 Sep 13;7(37):59058-59069. doi: 10.18632/oncotarget.10175.

32.

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.

Jansen MP, Martens JW, Helmijr JC, Beaufort CM, van Marion R, Krol NM, Monkhorst K, Trapman-Jansen AM, Meijer-van Gelder ME, Weerts MJ, Ramirez-Ardila DE, Dubbink HJ, Foekens JA, Sleijfer S, Berns EM.

Oncotarget. 2016 Jul 12;7(28):43412-43418. doi: 10.18632/oncotarget.9727.

33.

Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.

De Marchi T, Foekens JA, Umar A, Martens JW.

Drug Discov Today. 2016 Jul;21(7):1181-8. doi: 10.1016/j.drudis.2016.05.012. Epub 2016 May 24. Review.

PMID:
27233379
34.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2. Erratum in: Nature. 2019 Feb;566(7742):E1.

35.

Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis.

Weerts MJ, Sieuwerts AM, Smid M, Look MP, Foekens JA, Sleijfer S, Martens JW.

Oncotarget. 2016 May 17;7(20):29166-76. doi: 10.18632/oncotarget.8688.

36.

The advantage of laser-capture microdissection over whole tissue analysis in proteomic profiling studies.

De Marchi T, Braakman RB, Stingl C, van Duijn MM, Smid M, Foekens JA, Luider TM, Martens JW, Umar A.

Proteomics. 2016 May;16(10):1474-85. doi: 10.1002/pmic.201600004. Epub 2016 Apr 28.

PMID:
27030549
37.

GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.

Liu J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, Smid M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW.

Cancer Lett. 2016 Jun 28;376(1):104-9. doi: 10.1016/j.canlet.2016.03.038. Epub 2016 Mar 24.

38.

Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.

De Marchi T, Kuhn E, Dekker LJ, Stingl C, Braakman RB, Opdam M, Linn SC, Sweep FC, Span PN, Luider TM, Foekens JA, Martens JW, Carr SA, Umar A.

J Proteome Res. 2016 Apr 1;15(4):1230-42. doi: 10.1021/acs.jproteome.5b01119. Epub 2016 Mar 18.

PMID:
26958999
39.

Global proteomic characterization of microdissected estrogen receptor positive breast tumors.

De Marchi T, Liu NQ, Sting C, Smid M, Tjoa M, Braakman RB, Luider TM, Foekens JA, Martens JW, Umar A.

Data Brief. 2015 Oct 8;5:399-402. doi: 10.1016/j.dib.2015.09.034. eCollection 2015 Dec.

40.

An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.

Reijm EA, Sieuwerts AM, Smid M, Vries JB, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, van Galen A, Kraan J, Jansen MP, Gratama JW, Foekens JA, Martens JW, Berns EM, Sleijfer S.

BMC Cancer. 2016 Feb 18;16:123. doi: 10.1186/s12885-016-2155-y.

41.

A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds.

Mustafa DA, Sieuwerts AM, Smid M, de Weerd V, van der Weiden M, Meijer-van Gelder ME, Martens JW, Foekens JA, Kros JM.

PLoS One. 2015 Dec 30;10(12):e0144097. doi: 10.1371/journal.pone.0144097. eCollection 2015.

42.

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.

De Marchi T, Timmermans AM, Smid M, Look MP, Stingl C, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, van Deurzen CH, Luider TM, Foekens JA, Martens JW, Umar A.

Oncotarget. 2016 Jan 19;7(3):3098-110. doi: 10.18632/oncotarget.6521.

43.

Using second harmonic generation to predict patient outcome in solid tumors.

Burke K, Smid M, Dawes RP, Timmermans MA, Salzman P, van Deurzen CH, Beer DG, Foekens JA, Brown E.

BMC Cancer. 2015 Nov 24;15:929. doi: 10.1186/s12885-015-1911-8.

44.

Understanding drugs in breast cancer through drug sensitivity screening.

Uhr K, Prager-van der Smissen WJ, Heine AA, Ozturk B, Smid M, Göhlmann HW, Jager A, Foekens JA, Martens JW.

Springerplus. 2015 Oct 15;4:611. doi: 10.1186/s40064-015-1406-8. eCollection 2015.

45.

4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.

De Marchi T, Liu NQ, Stingl C, Timmermans MA, Smid M, Look MP, Tjoa M, Braakman RB, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, Luider TM, Foekens JA, Martens JW, Umar A.

Mol Oncol. 2016 Jan;10(1):24-39. doi: 10.1016/j.molonc.2015.07.004. Epub 2015 Aug 7.

46.

Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.

Dalm SU, Sieuwerts AM, Look MP, Melis M, van Deurzen CH, Foekens JA, de Jong M, Martens JW.

J Nucl Med. 2015 Oct;56(10):1487-93. doi: 10.2967/jnumed.115.160739. Epub 2015 Aug 6.

47.

Carcinoma in situ to invasive breast cancer.

van Deurzen CH, Foekens JA.

Oncoscience. 2015 Jun 17;2(6):570-1. eCollection 2015. No abstract available.

48.

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S.

Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15.

PMID:
26188394
49.

Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer.

Onstenk W, Sieuwerts AM, Weekhout M, Mostert B, Reijm EA, van Deurzen CH, Bolt-de Vries JB, Peeters DJ, Hamberg P, Seynaeve C, Jager A, de Jongh FE, Smid M, Dirix LY, Kehrer DF, van Galen A, Ramirez-Moreno R, Kraan J, Van M, Gratama JW, Martens JW, Foekens JA, Sleijfer S.

Cancer Lett. 2015 Jun 28;362(1):36-44. doi: 10.1016/j.canlet.2015.03.020. Epub 2015 Mar 19.

PMID:
25797316
50.

Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant.

van Roosmalen W, Le Dévédec SE, Golani O, Smid M, Pulyakhina I, Timmermans AM, Look MP, Zi D, Pont C, de Graauw M, Naffar-Abu-Amara S, Kirsanova C, Rustici G, Hoen PA, Martens JW, Foekens JA, Geiger B, van de Water B.

J Clin Invest. 2015 Apr;125(4):1648-64. doi: 10.1172/JCI74440. Epub 2015 Mar 16.

Supplemental Content

Loading ...
Support Center